Gene · 554
AVPR2: arginine vasopressin receptor 2
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. AVPR2: arginine vasopressin receptor 2. Genes, record 554. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/554
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P30518 | Vasopressin V2 receptor | 371 | 43 | Ensembl, GeneID, HGNC |
Source UniProt
Patents53
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026062654 A | 2026-04-10 | 58 | P30518 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 37811 | P30518 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 37812 | P30518 | Espacenet |
| WO 2025196440 A1 | 2025-09-25 | 2 | P30518 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 551 | P30518 | Espacenet |
| JP 2025126890 A | 2025-08-29 | 7 | P30518 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 551 | P30518 | Espacenet |
| JP 2025062604 A | 2025-04-14 | 6184 | P30518 | Espacenet |
| JP 2025062604 A | 2025-04-14 | 6185 | P30518 | Espacenet |
| JP 2025024198 A | 2025-02-19 | 9294 | P30518 | Espacenet |
1 to 10 of 53
See all 53 patentsDrugs14
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| ARGIPRESSIN TANNATE | CHEMBL2108986 | Vasopressin receptor agonist | AGONIST | ChEMBL |
| CONIVAPTAN | CHEMBL1755 | Vasopressin V2 receptor antagonist | ANTAGONIST | ChEMBL |
| CONIVAPTAN HYDROCHLORIDE | CHEMBL1201108 | Vasopressin V2 receptor antagonist | ANTAGONIST | ChEMBL |
| DESMOPRESSIN | CHEMBL1429 | Vasopressin receptor agonist | AGONIST | ChEMBL |
| DESMOPRESSIN ACETATE | CHEMBL1200556 | Vasopressin receptor agonist | AGONIST | ChEMBL |
| LIXIVAPTAN | CHEMBL49429 | Vasopressin V2 receptor antagonist | ANTAGONIST | ChEMBL |
| LYPRESSIN | CHEMBL1200690 | Vasopressin receptor agonist | AGONIST | ChEMBL |
| MOZAVAPTAN | CHEMBL420762 | Vasopressin V2 receptor antagonist | ANTAGONIST | ChEMBL |
| PECAVAPTAN | CHEMBL4594444 | Vasopressin V2 receptor antagonist | ANTAGONIST | ChEMBL |
| SATAVAPTAN | CHEMBL2107777 | Vasopressin V2 receptor antagonist | ANTAGONIST | ChEMBL |
1 to 10 of 14
See all 14 drugsTrials246
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07460908 | TERLIPRESSIN | ClinicalTrials.gov | ||
| NCT07423156 | VASOPRESSIN | PHASE3 | ClinicalTrials.gov | |
| NCT07304466 | TERLIPRESSIN | ClinicalTrials.gov | ||
| NCT07255378 | VASOPRESSIN | ClinicalTrials.gov | ||
| NCT07252401 | TERLIPRESSIN | ClinicalTrials.gov | ||
| NCT07233850 | TERLIPRESSIN | PHASE2 | ClinicalTrials.gov | |
| NCT07179991 | DESMOPRESSIN | ClinicalTrials.gov | ||
| NCT07052084 | VASOPRESSIN | PHASE3 | ClinicalTrials.gov | |
| NCT07028645 | DESMOPRESSIN | ClinicalTrials.gov | ||
| NCT06855758 | TERLIPRESSIN | ClinicalTrials.gov |
1 to 10 of 246
See all 246 trialsNIH grants1,257
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | AVPR2 papers | Newest fiscal year |
|---|---|---|---|
| R01HL016037 | Molecular Regulation of Cardiovascular 7 TM Receptors | 23 | 2025 |
| ZIAHL001285 | Solute And Water Transport In Renal Epithelia | 14 | 2025 |
| ZIAHL006129 | Computational Tools for Proteomics | 14 | 2025 |
| R01DA012864 | Mechanisms and Cellular Function of Opioid Receptor Endocytosis | 10 | 2025 |
| P30DK043351 | Center for the Study of Inflammatory Bowel Disease at Massachusetts General Hospital | 7 | 2025 |
| R01EY011500 | Structure-function studies of visual arrestin | 6 | 2025 |
| R01HL122010 | Decrypting Variants of Uncertain Significance in Long-QT Syndrome | 6 | 2025 |
| P51OD011132 | Emory National Primate Research Center | 5 | 2025 |
| R01GM122798 | Biasing CXCR3 Signaling to Modulate the Inflammatory Response | 5 | 2025 |
| R01MH054137 | Structure and Function of Dopamine Receptors | 5 | 2025 |
1 to 10 of 1,257Source NIH's project files
See all 1,257 nih grantsPapers2,697
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Disappearance of Posterior Pituitary Hyperintensity in Arginine Vasopressin Resistance: A Case Report. | Turk Arch Pediatr | 2026 | 42826241 | PubTator, text mining | PubMed |
| Functional characterization of genetic variants associated with rare inherited renal disorders in the Sri Lankan population. | Mol Genet Genomics | 2026 | 42814169 | PubTator, text mining | PubMed |
| Methylation Mesa define functional regulatory elements for targeted gene activation. | Nat Commun | 2026 | 42786170 | PubTator, text mining | PubMed |
| Impact of fluconazole in vasopressin 2 receptor-related congenital arginine vasopressin resistance. | Kidney Int | 2026 | 42785711 | PubTator, text mining | PubMed |
| Large-scale organoid-derived cyst cultures as a drug discovery platform for polycystic kidney disease. | Kidney Int | 2026 | 42772449 | PubTator, text mining | PubMed |
| Tolvaptan in heart failure: Contemporary evidence and a framework for precision decongestion. | Heart Fail Rev | 2026 | 42714631 | PubTator, text mining | PubMed |
| Nephrogenic Syndrome of Inappropriate Antidiuresis: Case Report and Genetic Perspectives. | Nephrology (Carlton) | 2026 | 42685775 | PubTator, text mining | PubMed |
| Universal pipeline for high-resolution GPCR structure determination. | Nat Struct Mol Biol | 2026 | 42665663 | PubTator, text mining | PubMed |
| SGLT2 inhibitors in autosomal dominant polycystic kidney disease: rationale, evidence gaps, and ongoing clinical trials. | Int Urol Nephrol | 2026 | 42584781 | PubTator, text mining | PubMed |
| X-Linked Nephrogenic Diabetes Insipidus Associated with the AVPR2 c.964C>T (p.Pro322Ser) Variant: A Family Case Series. | J Clin Med | 2026 | 42513428 | PubTator, text mining | PubMed |
1 to 10 of 2,697
See all 2,697 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/554
GET https://conductscience.org/api/genes/v1/554/patents?page=2